



Cilostazol Aqueous Solubility as a Function of Solubilizer Concentration Simulated Intestinal Fluid w/o Enzyme, pH 6.8, 37°C








Release of Cilostazol from Examples 6-1 and 6-2 USP App. I, 100 rpm; 37°C, 1000 ml SIF w/o enzyme (pH 6.8)





Release of Carvedilol from Example 10-1 and Comparator 10-1 Extended release tester; 10 rpm, $37.0\pm0.1^{\circ}$ C, 100 ml






Figure 6



Extended Release of Zafirlukast in 250 ml SGF (pH1.2) for 2 Hours and Subsequently in 250 ml SIF (pH 6.8) for 22 Hours at 37°C (USP I, 100 rpm)



12 - о- Example 12-8 —**←**—Example 12-4 10 Release of Zafirlukast from Example 12-4 and 12-8 6 USP Apparatus I; 100 rpm, 37.0±0.1°C; 0-2h: 250 ml SGF, 2+h: 250 ml SIF (pH 6.8) ∞ Time (Hours) **1** %0 120% 기 100% %08 %09 40% Zafirlukast Released (%)

Figure 9

Release of Pioglitazone from Example 15-1, 15-2, and 15-3 USP Apparatus II; 100 rpm, 37.0±0.1°C, 250 ml SIF (pH 6.8)




Figure 10